Denia

Researchers are investigating how CDR132L, a potential new medicine, affects the structure and function of the heart in people living with heart failure with reduced or mildly reduced ejection fraction and left ventricular hypertrophy. This Phase 2 study compares CDR132L to a placebo, where participants receive either treatment randomly. The study aims to evaluate changes in a specific biomarker, microRNA-132-3p, over 24 weeks, with the total study duration lasting about 60 weeks. Participants will receive either CDR132L or a placebo through an intravenous infusion once every 4 weeks for a total of 48 weeks. The treatments are given under a double-blind design, meaning neither the participants nor the researchers know who receives which treatment until the study ends. This allows for a fair comparison of the effects of CDR132L versus placebo on heart structure and function. During the study, participants will undergo regular assessments including laboratory tests to measure heart-related biomarkers and imaging tests such as echocardiography to monitor heart structure and function. Researchers will track changes from baseline to week 24 in microRNA-132 levels and continue monitoring participants through the 60-week study period to evaluate safety and treatment effects. Ongoing clinical evaluations and safety checks will help ensure participant well-being throughout the trial.

This trial investigates the effectiveness and safety of combining lower limb compression therapy with parenteral diuretics versus using parenteral diuretics alone in adults with decompensated heart failure. The study focuses on patients who show mainly systemic tissue congestion without intravascular systemic congestion. The goal is to evaluate whether adding compression therapy can improve outcomes in this patient group. Participants are randomly assigned to receive either standard treatment with parenteral furosemide alone or furosemide combined with compression therapy using the UrgoK2 or UrgoK2 Lite multicomponent compressive bandage system. The bandages provide sustained ankle pressure and are applied for up to 72 hours while furosemide dosing is determined by the treating healthcare professional based on clinical judgment. During the study, researchers monitor participants' urine sodium excretion and weight over 24 hours to assess treatment effects. Patients will undergo evaluations including ultrasonography of the inferior vena cava and assessments of edema severity. Safety and efficacy are closely observed throughout the treatment period to understand the benefits and risks of adding compression therapy to diuretic use in this condition.

Researchers are comparing two types of blades used with videolaryngoscopes to see which is better for first-attempt tracheal intubation in patients admitted to intensive care units (ICU). This study focuses on critically ill patients who need intubation and aims to find out if the hyperangulated blade improves the success rate compared to the Macintosh blade, which is more similar to traditional laryngoscopy blades. The study is a prospective, multicenter, randomized trial designed to provide clarity on the best blade choice during ICU intubations. Participants will be randomly assigned to have their tracheal intubation performed using either a hyperangulated videolaryngoscope blade or a Macintosh videolaryngoscope blade during their first attempt. Both groups use videolaryngoscopy as the device for intubation, but differ in the blade type. The study evaluates the success of intubation on the first try using these different blades. During the study, researchers will monitor the intubation process to measure the percentage of successful first attempts. They will also track any complications or difficulties related to intubation. The study includes adult ICU patients from 18 to 90 years old who require intubation. Data on intubation success and related outcomes will help determine which blade offers better airway management in critically ill patients.

Researchers are evaluating how inflammatory bowel disease (IBD) activity affects frailty in patients aged 60 years and older. This observational, multicenter, prospective, and longitudinal study also aims to understand how frailty influences the risk of hospitalization and death in this population. The study seeks to determine if frailty and its related complications can be reversed with proactive treatment and which frailty index best predicts these risks in patients with active IBD. At the start of the study, four clinical frailty indices will be calculated along with clinical information about IBD, including diagnosis, disease characteristics, treatments, and comorbidities. Patients will be followed for 12 months with three visits at 3, 6, and 12 months. During these visits, frailty, comorbidities, disease activity, changes in medical treatments, adverse effects, hospitalizations, and mortality will be reassessed to monitor progress and outcomes. Participants will have detailed assessments including frailty scales and clinical data collection at the beginning and during follow-up visits. Researchers will track hospitalizations and mortality over the year-long period. This monitoring will help evaluate the impact of both IBD activity and frailty on patient health outcomes in a real-world setting.

Researchers are evaluating the effects of maridebart cafraglutide, given alongside standard care, in reducing heart failure events such as hospitalizations, urgent visits, cardiovascular deaths, and improving symptoms in people with heart failure who have preserved or mildly reduced ejection fraction and are obese. This is a global phase 3, multicenter trial with a two-part design including a double-blind period followed by an open-label extension. The first part will end once around 850 key events have been recorded. Participants will receive either maridebart cafraglutide or a placebo, both administered by injection under the skin. The study includes an initial randomized, double-blind phase and a later open-label extension where all participants may receive the active treatment. The trial is designed to monitor participants over time to assess the safety and effects of the treatment compared to placebo. During the trial, participants will undergo assessments including monitoring for cardiovascular events, heart failure symptoms, and laboratory tests such as NT-proBNP levels. Researchers will track time until the first occurrence of cardiovascular death or heart failure events over approximately 35 months. Safety evaluations, adherence to treatment, and ongoing health status will be followed throughout the study period.

This study is designed to identify individuals who may be eligible for future Roche clinical trials focused on Alzheimer's disease. It serves as a pre-screening step to evaluate participants based on biomarker status and cognitive performance. The study targets adults aged 50 to 90 years who have experienced memory concerns recently, with or without a diagnosis of mild cognitive impairment or dementia due to Alzheimer's disease. Participants do not receive any intervention during this study. Instead, they will have their blood drawn to measure the concentration of a biomarker called pTau217 and will undergo a cognitive assessment using the ISLT (International Shopping List Test) on the first day of participation. This process helps researchers determine potential eligibility for more extensive Alzheimer's disease trials. During the study, participants will be evaluated for memory concerns and cognitive function through blood tests and cognitive scoring. Researchers will monitor biomarker levels and cognitive scores on the first day to help assess trial eligibility. The study includes safety assessments to ensure participants can safely complete these procedures, with participation lasting for the duration of the pre-screening evaluations.